Which factors favor extended dual antiplatelet therapy beyond one year in ACS patients with low bleeding risk?

Selecting an optimal duration of dual antiplatelet therapy (DAPT) for a given patient (whether "extended" or "short" in comparison to one year) must be personalized, with a calculus that considers an individual's competing risks of bleeding and thrombosis as a function of time.

Accordingly, without b...